|Bid||245.52 x 900|
|Ask||245.56 x 800|
|Day's Range||243.08 - 253.48|
|52 Week Range||144.00 - 275.87|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||36.76|
|Earnings Date||Jan. 27, 2022 - Jan. 31, 2022|
|Forward Dividend & Yield||3.40 (1.57%)|
|Ex-Dividend Date||May 13, 2021|
|1y Target Est||262.24|
The U.S. Food and Drug Administration on Friday authorized the use of Eli Lilly's COVID-19 dual-antibody therapy in treating mild to moderate symptoms in all children, including newborns, who are at risk of severe illness. The therapy, bamlanivimab plus etesevimab, was previously authorized for children aged 12 years and older and weighed at least 88 pounds. "Children under one year of age, who are exposed to the virus that causes COVID-19, may be at particularly high risk for severe COVID-19 and this authorization addresses the medical needs of this vulnerable population," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.
Mexico's health regulator Cofepris said on Wednesday it had approved U.S. pharmaceutical firm Eli Lilly and Co's antibody treatment against COVID-19 for emergency use with infected patients at risk from comorbidities. Cofepris said in a statement it had granted the emergency use of Lilly's injectable combination of bamlanivimab and etesevimab to treat mild to moderate cases of coronavirus in people above the age of 12 who weigh at least 40 kilograms. The U.S. Food and Drug Administration had previously approved emergency use of the combination.
An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.